


FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D



3
4
5
S
T
100 µm
6
7
EV
shRNA1

FIG. 1E



Product-Limit Survival Estimates
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
20
40
60
80
100
Months To Relapse
iNOS SCORE
A: 3 AND 4
B: 5 AND 6
C:7
LOG-RANK TEST
CHI SQUARE: 5.6
P VALUE: 0.05
+ CENSORED

FIG. 1F




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 2F




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 3E




FIG. 3F




FIG. 3G




FIG. 3J




FIG. 3I




FIG. 3H



L-NAME_MDA-MB-231 xenografts
Tumor Volume (mm3)
1000.0
800.0
600.0
400.0
200.0
0.0
VEHICLE
L-NAME (80mg/kg,DAILY)
***
0
3
7
10
14
17
21
24
28
31
35
Days

FIG. 4A



Primary MS_MDA-MB-231
Secondary MS_MDA-MB-231
MSFE (%)
120
100
80
60
40
20
0
**
VEHICLE
L-NAME
VEHICLE
L-NAME

FIG. 4B




FIG. 4C

LIMITING DILUTION ASSAY (n=5)		
	1.5 WEEKS	2.5 WEEKS
	$5x10^5$ CELLS	$1x10^5$ CELLS
VEHICLE	5/5	5/5
L-NAME	3/5	0/5 *

FIG. 4D




FIG. 5A




FIG. 5B




FIG. 5C



CHEMO
COMBO
Apoptosis (%)
0
2
4
6
8
10
12
14
CHEMO
COMBO
**
Cleaved caspase-3

FIG. 5D



Primary MS_MDA-MB-231
MSFE (%)
0
20
40
60
80
100
120
VEHICLE
L-NMMA
CHEMO
COMBO
**
**
*
Secondary MS_MDA-MB-231
MSFE (%)
0
20
40
60
80
100
120
VEHICLE
L-NMMA
CHEMO
COMBO
****
****
****
****

FIG. 5E

LIMITING DILUTION ASSAY (n=12)		
	5 WEEKS	6 WEEKS
	$5x10^4$ CELLS	$2x10^4$ CELLS
VEHICLE	12/12	6/12
L-NMMA	1/12 *	3/12 *
CHEMO	8/12	10/12
COMBO	4/12 *	5/12 *

FIG. 5F




FIG. 6A

FIG. 6B

FIG. 6C



Survival proportions
Percent survival
150
100
50
0
0
20
40
60
80
100
Days
VEHICLE
COMBO
CHEMO
****

FIG. 6D



L-NMMA SUM159 xenografts
Tumor Volume (mm3)
1000
800
600
400
200
0
0
3
7
10
14
17
21
24
28
Days
VEHICLE
AMIODOPINE
CHEMO
COMBO
***
DOCETAXEL(20mg/kg)
L-NMMA (200mg/kg)
AMLODIPINE (10mg/kg)

FIG. 6E



Primary MS_MDA-MB-231
VEHICLE
1mM
2mM
4mM
1400W
L-NMMA
L-NAME

FIG. 7A



Secondary MS_MDA-MB-231
1400W
L-NMMA
L-NAME

FIG. 7B



Primary MS_SUM159
VEHICLE
1mM
2mM
4mM
1400W
L-NMMA
L-NAME

FIG. 8A



Secondary MS_SUM159
1400W
L-NMMA
L-NAME

FIG. 8B



SUM159
Proliferation (%)
0
20
40
60
80
100
120
140
VEHICLE
1
2
5
L-NAME (mM)
****
****
****
MDA-MB-231
Proliferation (%)
0
20
40
60
80
100
120
140
VEHICLE
1
2
5
L-NAME (mM)
****
****
****

FIG. 9A



Primary MS_SUM159
MSFE (%)
0
20
40
60
80
100
120
140
VEHICLE
1
2
5
L-NAME (mM)
***
****
Primary MS_MDA-MB-231
MSFE (%)
0
20
40
60
80
100
120
140
VEHICLE
1
2
5
L-NAME (mM)
****
****
****

FIG. 9B



Secondary MS_SUM159
MSFE (%)
0
20
40
60
80
100
120
140
VEHICLE
1
2
5
L-NAME (mM)
***
****
****
Secondary MS_MDA-MB-231
MSFE (%)
VEHICLE
1
2
5
L-NAME (mM)
****
****

FIG. 9C



SUM159
Migration index (%)
0
20
40
60
80
100
120
VEHICLE
0.1
1
10
100
1400W (μM)
***
****
****
****
MDA-MB-231
Migration index (%)
VEHICLE
0.1
1
10
100
1400W (μM)
**
***
**
***

FIG. 9D




SUM159
Migration index (%)
120
100
80
60
40
20
0
VEHICLE
0.1
1
10
100
L-NMMA (μM)
**
**
**
MDA-MB-231
Migration index (%)
120
100
80
60
40
20
0
VEHICLE
0.1
1
10
100
L-NMMA (μM)
*

FIG. 9E






FIG. 10A




FIG. 10C




FIG. 10B




FIG. 10D




FIG. 10E




FIG. 10F



HIF1alpha_MDA-MB-231
Relative quantity (arbitrary units)
1.5
1
0.5
0
VEHICLE
1
2
4
1400W (mM)
*
**
**
HIF1alpha_SUM159
Relative quantity (arbitrary units)
2
1.5
1
0.5
0
VEHICLE
1
2
4
1400W (mM)
*
**

FIG. 10G




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E




FIG. 11F




FIG. 11G




FIG. 11H




FIG. 11I




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D

LIMITING DILUTION ASSAY n=12			
	7 WEEKS	9 WEEKS	
	$5x10^4$ CELLS	$2x10^4$ CELLS	
VEHICLE	12/12	7/12	
L-NMMA	4/12	0/12	*
CHEMO	12/12	3/12	
COMBO	6/12	* 0/12	*

FIG. 13E



Vehicle
40.3%
Q1
Q2
Q3
Q4
APC-A
FITC-A
L-NMMA
40%
Chemo
49.2%
Combo
45.6%
CD44
CD24

FIG. 14A



Vehicle
L-NMMA
Chemo
Combo
92%
90%
93%
86%
Q1
Q2
Q3
Q4
APC-A
FITC-A
CD44
CD24
10^2
10^3
10^4
10^5

FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 14F




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 15E




FIG. 15F




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 16E




FIG. 16F




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B




FIG. 20C




FIG. 20D